Granulosa cell tumor of the ovary.
Adult granulosa cell tumor (GCT) of the ovary is oftentimes a hormonally active, stromal cell neoplasm that is distinguished by its ability to secrete sex steroids such as estrogen. Patients may present with vaginal bleeding caused by endometrial hyperplasia or uterine cancer as a result of prolonged exposure to tumor-derived estrogen. In addition, GCT is a vascular tumor that may occasionally rupture and result in abdominal pain, hemoperitoneum, and hypotension, mimicking an ectopic pregnancy in younger patients. GCT is usually associated with a mass on pelvic examination that is subsequently confirmed on ultrasonography. Surgery is required for definitive tissue diagnosis, staging, and tumor debulking. In older women, a total abdominal hysterectomy and bilateral salpingooophorectomy are typically performed. In women of childbearing age, a more conservative unilateral salpingo-oophorectomy may be performed, assuming that careful staging reveals that the disease has not extended outside of the involved ovary and that a concomitant uterine cancer has been excluded. Survival of patients with GCT is generally excellent because most patients present with early-stage disease, although certain high-risk patient groups may be identified. Stage is the most important prognostic factor, with a higher risk of relapse being associated with stages II through IV disease. In addition, patients with stage I disease associated with features such as large tumor size, high mitotic index, or tumor rupture may also be at higher risk in some series. The value of postoperative adjuvant therapy for high-risk patients has not been investigated by prospective randomized trials, which are difficult to perform because of the rarity of this tumor. Nonetheless, the use of adjuvant chemotherapy or radiation has sometimes been associated with prolonged disease-free survival in patients with high-risk features. Because of the propensity of GCT to recur years after initial diagnosis, prolonged surveillance with serial physical examination and serum tumor markers such as estradiol and inhibin is reasonable.
Schumer
Susan Tinsley
ST
Program in Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. scannist@caregroup.harvard.edu
Cannistra
Stephen A
SA
D000367:Age Factors; D054304:Anti-Mullerian Hormone; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D017024:Chemotherapy, Adjuvant; D002979:Climacteric; D004958:Estradiol / Q000097:blood; D005260:Female; D006023:Glycoproteins; D006106:Granulosa Cell Tumor / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D006131:Growth Inhibitors / Q000032:analysis; D006801:Humans; D015994:Incidence; D007265:Inhibins / Q000097:blood; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D011159:Population Surveillance; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D015996:Survival Rate; D013735:Testicular Hormones / Q000032:analysis; D014481:United States / Q000453:epidemiology
D014408:Biomarkers, Tumor; D006023:Glycoproteins; D006131:Growth Inhibitors; D009944:Organoplatinum Compounds; D013735:Testicular Hormones; D004958:Estradiol; D007265:Inhibins; D054304:Anti-Mullerian Hormone